Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The primary goal of this trial is to determine if individuals with acute ischemic stroke
treated with a full dose of IV recombinant tissue plasminogen activator (rt-PA) plus IV
eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome
than individuals treated with standard IV rt-PA alone.
Phase:
Phase 2
Details
Lead Sponsor:
Arthur Pancioli
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)